ArticleBMC pediatrics2025
Growth and pubertal outcome of three-years medical treatment of peripheral precocious puberty in a boy with McCune-Albright Syndrome: a case report.
Article in BMC pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPeripheral precocious puberty (PPP) is an endocrine disorder characterized by premature, autonomous gonadal or extragonadal sexual steroid secretion. Accounting for about 20% of cases of precocious puberty, PPP is usually caused by rare diseases, including congenital adrenal hyperplasias, hormone-secreting gonadal and adrenal tumours, and McCune-Albright Syndrome (MAS). MAS is a rare, genetic disorder, mainly characterized by bone dysplasia, skin hyperpigmentation, and endocrine, hyperfunctioning disorders, including, as reported, PPP. Being a rare disease, PPP management in MAS patients is currently anecdotically reported, and no systematic approach is granted. CASE PRESENTATION: A four years and two months boy was admitted in our department due to precocious pubarche and recent growth acceleration. At physical examination, he showed cafè-au-lait skin macules on thorax, abdomen, and posterior neck, and at hormonal evaluation he showed evidence of PPP, confirmed at both baseline and stimulated gonadotropin and testosterone levels. Due to the clinical features, he was diagnosed with MAS, that was further confirmed by the evidence of bone skull and testicular lesions; a thyroid lesion was also reported, but its relationship with MAS was questioned. He therefore started combined treatment with androgen receptor blocker bicalutamide and aromatase inhibitor anastrazole, that were able to significantly reduce growth acceleration and to stop pubertal progression. He safely continued combined treatment for three years, showing good efficacy on growth and pubertal outcome.
conclusionCombined treatment with bicalutamide and anastrozole is a safe and effective long-term therapeutic approach to PPP in MAS boys, although evidences on its use are scarce; therefore, wider studies including larger populations deriving from different centres should be performed to obtain general consensus.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.